Evaluation of the Effect of Suppressing CD44 Gene Expression on Sensitization of HL-60 Cells to Danrobisin

Abstract

Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia that is different from other acute leukemias in coagulopathy and treatment. The disease is characterized by cellular morphology and specific immunophenotype. Acute promyelocytic leukemia (APL) is the clonal proliferation of immature myeloid cell line precursors in bone marrow and extracellular tissues. Drug resistance in treatment failure plays an important role in the immortality of these cells and disease recurrence. Examination of many factors, including cell surface markers, cell signaling and cell junctions in the bone marrow microenvironment play an important role in the proliferation and recurrence of malignancy. Past studies have shown that signaling caused by overexpression of CD44 molecules on cancer stem cells inhibits apoptosis and resistance to the cytotoxic effects of chemotherapy drugs in various cancers. Therefore, high expression of CD44 is associated with poor prognosis in patients. Results: The results of the study show that CD44-specific siRNA in combination therapy with danurobicin effectively reduces the survival of HL60 cancer cells and induces apoptosis and growth inhibition and drug resistance in this cell line. Be considered as an effective treatment strategy in the treatment of malignancies.